Turn Therapeutics Inc. (TTRX)
$9.82-$0.27 (-2.67%) Today
Latest TTRX Insider Trades
Zuraiz Chaudhary - OfficerOpen-market purchase
Zuraiz Chaudhary - OfficerZuraiz Chaudhary - OfficerZuraiz Chaudhary - OfficerZuraiz Chaudhary - Officer
Abraham ChesedZuraiz Chaudhary - OfficerTurn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
https://www.turntherapeutics.comSEC filings for TTRX on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 4 | 339,584 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
22 Form 4 filings on record, the earliest from Oct 8, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Martin William Dewhurst - Director | Grant or award | Stock option (right to buy) | 71,666 | $0.00 | - | |
 Andrew Gengos - Director | Grant or award | Stock option (right to buy) | 95,000 | $0.00 | - | |
| Arthur F. Golden - Director | Grant or award | Stock option (right to buy) | 89,584 | $0.00 | - | |
 Kent Edward Kester - Director | Grant or award | Stock option (right to buy) | 83,334 | $0.00 | - | |
 Bradley Evan Burnam - Officer | Gift | Common Stock | 300,000 | $0.00 | - | |
| Bradley Evan Burnam - Officer | Gift | Common Stock | 300,000 | $0.00 | - | |
| Bradley Evan Burnam - Officer | Gift | Common Stock | 300,000 | $0.00 | - | |
| Bradley Evan Burnam - Officer | Gift | Common Stock | 300,000 | $0.00 | - | |
| Bradley Evan Burnam - Officer | Gift | Common Stock | 300,000 | $0.00 | - | |
| Arthur F. Golden - Director | Gift | Common Stock | 300,000 | $0.00 | - | |
| Zuraiz Chaudhary - Officer | Grant or award | Employee stock option (right to buy) | 80,000 | $0.00 | - | |
| Martin William Dewhurst - Director | Grant or award | Common Stock | 21,882 | $0.00 | - | |
| Zuraiz Chaudhary - Officer | Open-market purchase | Common Stock | 2,500 | $3.50 | $9K | |
| Arthur F. Golden - Director | Open-market purchase | Common Stock | 9,868 | $3.44 | $34K | |
| Arthur F. Golden - Director | Open-market purchase | Common Stock | 20,532 | $2.87 | $59K | |
| Zuraiz Chaudhary - Officer | Open-market purchase | Common Stock | 1,450 | $2.61 | $4K | |
| Zuraiz Chaudhary - Officer | Open-market purchase | Common Stock | 1,000 | $3.29 | $3K | |
| Zuraiz Chaudhary - Officer | Open-market purchase | Common Stock | 2,500 | $3.62 | $9K | |
| Abraham Chesed | Open-market purchase | Common Stock | 14,286 | $4.60 | $66K | |
| Zuraiz Chaudhary - Officer | Open-market purchase | Common Stock | 5,050 | $4.95 | $25K | |
| Arthur F. Golden - Director | Open-market purchase | Common Stock | 20,202 | $4.95 | $100K | |
| Zuraiz Chaudhary - Officer | Grant or award | Employee stock option (right to buy) | 240,000 | $0.00 | - | |
| Arthur F. Golden - Director | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Andrew Gengos - Director | Grant or award | Common Stock | 10,000 | $0.00 | - | |
 Neilesh Shailesh Ghodadra - Officer | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Kent Edward Kester - Director | Grant or award | Common Stock | 10,000 | $0.00 | - |
Turn Therapeutics Inc. (TTRX) had 4 insider filings in the last 90 days, with the most recent on 2026-06-08. The full record for TTRX runs to 22 Form 4 filings, the earliest from 2025-10-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TTRX were filed in the last 90 days. 9 purchases are on record for this company.
No insider sales of TTRX were filed in the last 90 days.
This page tracks TTRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TTRX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
